Sep 7 2009
CYTOO SA, a provider of innovative enabling technologies and products for high content cell analysis, premiered what it believes is the world's first and most comprehensive commercially available portfolio of cell adhesive micropattern products to the cell biology research community at the EMBO Meeting last week in Amsterdam.
Fluorescence image captured on a CYTOOchip showing an array of normalized cells.
The 2x2 sq.cm micropatterned glass substrate CYTOOchip™ is the only commercially available cell analysis tool based on a proprietary adhesive micropatterning technology that dramatically decreases cell variability thus resulting in much more robust and reliable cell analysis.
“CYTOOchips normalize cell architecture down to their internal organization and thus offer a unique possibility of mapping a Reference Cell™, explained co-CEO and co-founder Alexandra Fuchs, PhD. We target a wide range of applications, including cell signaling, cell adhesion and polarity, cell division or precise protein co-localization and thanks to our customers we have been discovering new applications since the commercial launch of CYTOOchips this past spring”.
Constantin Nelep, PhD, Sr. Product Manager, added: “In order to reply to the rapidly increasing demand from our customers and prospects interested in using CYTOO technology in living cell studies, we have expanded our CYTOOchip product offering with an easy-to-use live cell imaging accessory introduced this week at the EMBO Meeting. Moreover thanks to an integrated grid positioning system, our users can now perform comparative microscopy studies such as immunofluorescence staining of specific cells which were first followed in time lapse microscopy”. Dr. Fuchs concluded “We are very much encouraged by the real interest of EMBO Meeting attendees in CYTOO’s technology that will help them take a leap into highly reproducible quantitative cell analysis.”
Micropatterns are available in a variety of sizes and shapes and can even be custom designed to meet the particular requirements of an application. The introductory presentation of the CYTOOchips to the North American market will take place at the December, 2009 ASCB Conference in San Diego, California.
Incorporated in 2008 and based in Grenoble, France, CYTOO SA is a venture-backed company focused on the development, manufacture and commercialization of innovative products primarily focused on applications in cell based assays, high content analysis and cell screening for the life science research market. CYTOO, Inc., located in Boston, USA was recently established as a wholly owned subsidiary of CYTOO SA.
CYTOO has an exclusive worldwide license for the adhesive micropattern patent portfolio from the Curie Institute, France and the CNRS as well as patent license agreements with the CEA (Life Sciences Division) and Harvard University.